Articles
Plain explanations of what these assessments measure, written for the person having them and for the clinician reading the report.
-
Periodontal Disease and Dementia: A Screening Workflow
Severe periodontitis carries the dementia signal, GAIN excluded metabolically complex patients, and the dental chart rarely reaches the cognitive workup.
-
Gum Disease and Dementia: What Is Proven and What to Measure
Severe gum disease tracks with dementia risk, but the one drug trial failed. What the evidence shows, what Measura cannot test, and what it can measure.
-
Metaflammation Screening: What the Standard Panel Misses
Metaflammation is silent and the usual panel reads it late. Evidence tiers, who to measure, what the neutrophil count and waist add, and how to document it.
-
B Vitamins in Mild Cognitive Impairment: Measure Before It Is Late
B vitamins slowed atrophy in mild cognitive impairment and failed in Alzheimer’s disease. What that means for testing older patients, drug-related B12 loss, and screening workflow.
-
Metformin B12 Deficiency: Screening Beyond the Serum Level
Serum B12 undercalls tissue-level deficiency, and metformin users carry the most risk. The cohort and trial evidence, what a functional marker changes, and how to build it into standing orders.
-
Methylmalonic Acid Test: When a Normal B12 Is Not Enough
A B12 inside the normal range can still hide a shortfall at the level of your cells. What the methylmalonic acid test measures, who is most at risk, and what to ask for.
-
Statins and Dementia: Measuring Cognition in Patients on Statins
Trials show no cognitive harm on average; a reversible effect in a susceptible few is testable only against a baseline. The evidence and a measurement protocol.
-
Statins and Memory Loss: What to Measure Before Anyone Guesses
The brain makes its own cholesterol behind a barrier your lipid panel never sees. What the statin memory evidence shows, and how a cognitive baseline makes it testable.